Locus Biosciences, a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for bacterial and inflammatory diseases, entered a credit facility of up to $25 million with Hercules Capital.
Hercules Capital amended the existing term loan facility agreement it has with Axsome Therapeutics to increase the size of the facility to $300 million and the amount immediately available upon FDA approval of AXS-05 for major depressive disorder to $100 million at the company’s option.
Eloxx Pharmaceuticals entered into a debt facility of up to $30 million with Hercules Capital, a specialty financing lender for life science and technology companies. Eloxx has drawn the initial tranche of $12.5 million and used the proceeds to repay in full amounts outstanding under its existing debt facility.
Corium, a commercial-stage biopharmaceutical company, closed on a $235 million term loan agreement with Hercules Capital. Hercules Capital also reported it has originated more than $1.5 billion year to date in annual total gross debt and equity commitments in 2021, breaking its previous one-year record.
Phathom Pharmaceuticals, a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, obtained a $200 million term loan facility from Hercules Capital.
Better Therapeutics, a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, secured a loan facility for up to $50 million from Hercules Capital.
Hercules Capital, a specialty financing provider to venture, growth and established stage companies backed by venture capital and select private equity firms, has originated more than $1 billion year-to-date in annual total debt and equity commitments for the fourth consecutive year.
HiberCell, a biotechnology company developing therapeutics for the prevention of cancer relapse and metastasis, closed on a $30 million debt facility with Hercules Capital. In addition, HiberCell completed a Series B financing round for gross proceeds of $67.4 million.
SCYNEXIS secured a $60 million term loan facility with Hercules Capital and Silicon Valley Bank. The capital strengthens SCYNEXIS’ balance sheet ahead of the anticipated commercial launch of Brexafemme, an oral antifungal product for the treatment of vaginal yeast infections.
Hercules Capital and Silicon Valley Bank provided a loan facility of up to $75 million for Geron, supporting the company with access to non-dilutive financial resources to support its imetelstat development program.